Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:05 AM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 10,533 matching trials from the local directory fallback.
Filters: Active, not recruiting Clear all
Active, not recruiting Phase 2 Interventional

Cement Augmentation in Preventing Vertebral Body Compression Fracture Following Spine Stereotactic Radiosurgery in Patients With Solid Tumors and Spinal Metastases

NCT02387905
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in the Spine, Metastatic Malignant Solid Neoplasm
Interventions
Management of Therapy Complications, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Radiosurgery
Procedure · Other · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 8:08 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families

NCT02337452
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Questionnaire Administration, Web Site
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2048
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 8:49 PM EDT
Active, not recruiting Phase 2 Interventional

Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

NCT02250937
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Cladribine, Fludarabine Phosphate, Laboratory Biomarker Analysis, Peripheral Blood Stem Cell Transplantation, Pharmacological Study, Venetoclax
Procedure · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 70 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 9:54 PM EDT
Active, not recruiting Phase 2 Interventional

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

NCT02106988
View directory record Official record
Conditions
Lymphoma
Interventions
Carboplatin, Dexamethasone, Etoposide phosphate, Ifosfamide, Mesna, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2034
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 8:28 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Biobehavioral and Sociodemographic Characteristics of Long Term Survivors of Ovarian Cancer

NCT02043158
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Interview, Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
5
States / cities
West Hollywood, California • Iowa City, Iowa • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 10:32 PM EDT
Active, not recruiting Phase 1 Interventional

Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

NCT01955460
View directory record Official record
Conditions
Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
Biological · Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
12 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 9:12 PM EDT
Active, not recruiting Not applicable Interventional Results available

Reproductive Health Program in Patients With Cancer

NCT01806129
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Standard practice related to reproductive heath, Training modules, algorithm, referral development
Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
15 Years to 55 Years · Female only
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
109
States / cities
Jonesboro, Arkansas • Aurora, Colorado • Boulder, Colorado + 80 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 9, 2026, 8:18 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer

NCT01688492
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ipilimumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
3
States / cities
Evanston, Illinois • New York, New York • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 6:35 PM EDT
Active, not recruiting Phase 2 Interventional

Proton Beam Therapy (PBT) Versus Intensity-Modulated Radiation Therapy (IMRT) Trial

NCT01512589
View directory record Official record
Conditions
Esophageal Cancer
Interventions
Intensity Modulated Radiation Therapy (IMRT), Proton Beam Therapy (PBT), Questionnaires
Radiation · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 15, 2026, 8:11 AM EDT
Active, not recruiting Phase 1 Interventional

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

NCT01430390
View directory record Official record
Conditions
Acute Lymphocytic Leukemia, Lymphoma
Interventions
Biological/Genetically Modified T cells, Cyclophosphamide-based chemotherapy
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 17, 2026, 11:05 AM EDT
Active, not recruiting Phase 2 Interventional

Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia

NCT01424982
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Methotrexate, Ponatinib, Ponatinib Hydrochloride, Prednisone, Rituximab, Vincristine, Vincristine Sulfate
Drug · Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 16, 2026, 1:13 PM EDT
Active, not recruiting Phase 2 Interventional

Follow-up After Metastasectomy in Patients With Kidney Cancer

NCT00918775
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Follow-Up Care, Laboratory Biomarker Analysis
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 6:40 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Text Message and Mail Delivery of Tailored Educational Materials to Improve Access to Resources for Smoking Cessation of Menthol Tobacco Cigarettes

NCT07857681
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Educational Intervention, Internet-Based Intervention, Smartphone Application-based Intervention, Smoking Cessation Intervention, Text Message-Based Navigation Intervention
Other · Behavioral
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 13, 2026, 10:28 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparison of Four Qualia Sleep Formulations on Sleep Quality : An Open-label 4-arm Pilot Study

NCT07744971
View directory record Official record
Conditions
Sleep Quality
Interventions
Qualia Sleep Formula A, Qualia Sleep Formula B, Qualia Sleep Formula C, Qualia Sleep Formula D
Dietary Supplement
Lead sponsor
Qualia Life Sciences
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Carlsbad, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 13, 2026, 8:00 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation

NCT07702578
View directory record Official record
Conditions
AML, MDS
Interventions
Control, TSC-101
Other · Drug
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
26
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Duarte, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 1:08 PM EDT
Active, not recruiting No phase listed Observational

Endometrial Cancer Vaginal Fluid Specimen Collection Study

NCT07544680
View directory record Official record
Conditions
Abnormal Uterine Bleeding (AUB), Atypical Endometrial Hyperplasia, Endometrial Cancer, Endometrial Hyperplasia With Atypia, Endometrial Intraepithelial Neoplasia
Interventions
Not listed
Lead sponsor
Exact Sciences Corporation
Industry
Eligibility
18 Years and older · Female only
Enrollment
4,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
5
States / cities
Sarasota, Florida • Scarborough, Maine • Murfreesboro, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 7:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

NCT07335796
View directory record Official record
Conditions
Prostate Cancer
Interventions
BMS-986165, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 16, 2026, 2:53 AM EDT
Active, not recruiting No phase listed Observational

Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors

NCT07259304
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Central Nervous System Neoplasm, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Clinical Stage IIA Cutaneous Melanoma AJCC v8, Clinical Stage IIB Cutaneous Melanoma AJCC v8, Clinical Stage IIC Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Melanoma AJCC v8, Hodgkin Lymphoma, Malignant Bone Neoplasm, Malignant Brain Neoplasm, Malignant Solid Neoplasm, Malignant Testicular Neoplasm, Non-Hodgkin Lymphoma, Pathologic Stage I Cutaneous Melanoma AJCC v8, Pathologic Stage IA Cutaneous Melanoma AJCC v8, Pathologic Stage IB Cutaneous Melanoma AJCC v8, Pathologic Stage II Cutaneous Melanoma AJCC v8, Pathologic Stage IIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIC Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Stage I Cervical Cancer AJCC v8, Stage I Colorectal Cancer AJCC v8, Stage I Differentiated Thyroid Gland Carcinoma AJCC v8, Stage I Ovarian Cancer AJCC v8, Stage I Thyroid Gland Medullary Carcinoma AJCC v8, Stage I Uterine Corpus Cancer AJCC v8, Stage IA Cervical Cancer AJCC v8, Stage IA Ovarian Cancer AJCC v8, Stage IA Uterine Corpus Cancer AJCC v8, Stage IA1 Cervical Cancer AJCC v8, Stage IA2 Cervical Cancer AJCC v8, Stage IB Cervical Cancer AJCC v8, Stage IB Ovarian Cancer AJCC v8, Stage IB Uterine Corpus Cancer AJCC v8, Stage IB1 Cervical Cancer AJCC v8, Stage IB2 Cervical Cancer AJCC v8, Stage IC Ovarian Cancer AJCC v8, Stage II Cervical Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Differentiated Thyroid Gland Carcinoma AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Thyroid Gland Medullary Carcinoma AJCC v8, Stage II Uterine Corpus Cancer AJCC v8, Stage IIA Cervical Cancer AJCC v8, Stage IIA Colorectal Cancer AJCC v8, Stage IIA Ovarian Cancer AJCC v8, Stage IIA1 Cervical Cancer AJCC v8, Stage IIA2 Cervical Cancer AJCC v8, Stage IIB Cervical Cancer AJCC v8, Stage IIB Colorectal Cancer AJCC v8, Stage IIB Ovarian Cancer AJCC v8, Stage IIC Colorectal Cancer AJCC v8, Stage III Cervical Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Differentiated Thyroid Gland Carcinoma AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Thyroid Gland Medullary Carcinoma AJCC v8, Stage III Uterine Corpus Cancer AJCC v8, Stage IIIA Cervical Cancer AJCC v8, Stage IIIA Colorectal Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Uterine Corpus Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Cervical Cancer AJCC v8, Stage IIIB Colorectal Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Uterine Corpus Cancer AJCC v8, Stage IIIC Colorectal Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Uterine Corpus Cancer AJCC v8, Stage IIIC1 Uterine Corpus Cancer AJCC v8, Stage IIIC2 Uterine Corpus Cancer AJCC v8
Interventions
Medical Device Usage and Evaluation, Quality-of-Life Assessment, Survey Administration
Other
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 39 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
3
States / cities
Los Angeles, California • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 16, 2026, 1:05 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age

NCT07207408
View directory record Official record
Conditions
Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersinia Pestis
Interventions
rF1V-1018
Biological
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 55 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
4
States / cities
Miami, Florida • El Dorado, Kansas • Las Vegas, Nevada + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 6:59 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Does Psychotherapy Change the Gut Microbiome in Women of Child-bearing Age?

NCT07200531
View directory record Official record
Conditions
Chronic Stress
Interventions
Psychotherapy
Behavioral
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 54 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 13, 2026, 11:28 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Lions Hearts: A Community Approach to Multigenerational Cardiovascular Disease Risk

NCT07147387
View directory record Official record
Conditions
Cardiovascular (CV) Risk
Interventions
Lion Hearts Family-Based Physical Activity Program
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
10 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
State College, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 15, 2026, 4:37 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

NCT07134088
View directory record Official record
Conditions
Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab
Drug
Lead sponsor
Amgen
Industry
Eligibility
28 Days and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Palo Alto, California • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 11:57 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.

NCT06995820
View directory record Official record
Conditions
Healthy
Interventions
AZD1613, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 13, 2026, 8:43 PM EDT
Active, not recruiting Phase 3 Interventional

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

NCT06894212
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, SEP-363856
Other · Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
35
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Rogers, Arkansas + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 14, 2026, 9:07 AM EDT